Focus: Perceptive is a UK-based medical imaging biotechnology company specializing in optical coherence tomography (OCT) and visualization technologies across neurology, ophthalmology, gastroenterology, and hematology. The company operates at a relatively early stage with a focused pipeline of imaging-based diagnostic and procedural tools.
Profile data last refreshed 17h ago · AI intelligence enriched 3w ago
Cooling — net -11 jobs in 30d
8 added, 19 removed. Slower than typical.
Perceptive is a high-risk, high-learning opportunity for early-career researchers and engineers willing to build imaging technology from the ground up in an underexplored diagnostic space.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Perceptive
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Perceptive's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Perceptive Discovery Launches Astatine-211 Study Capabilities in the US and UK - PR Newswire
Perceptive Discovery Launches Astatine-211 Study Capabilities in the US and UK PR Newswire
Perceptive Discovery & Nucleus RadioPharma partner to speed up radiopharmaceutical development - Indian Pharma Post
Perceptive Discovery & Nucleus RadioPharma partner to speed up radiopharmaceutical development Indian Pharma Post
Perceptive, Nucleus partner to support radiopharmaceutical development - Pharmaceutical Technology
Perceptive, Nucleus partner to support radiopharmaceutical development Pharmaceutical Technology
Perceptive Discovery and Nucleus RadioPharma Announce Strategic Partnership to Accelerate Radiopharmaceutical Development from Target to Clinic - PR Newswire
Perceptive Discovery and Nucleus RadioPharma Announce Strategic Partnership to Accelerate Radiopharmaceutical Development from Target to Clinic PR Newswire
8-K Filing: TELA Bio, Inc. (TELA) (CIK 0001561921) — FORM 8-K
FORM 8-K
8-K Filing: LISATA THERAPEUTICS, INC. (LSTA) (CIK 0000320017) — EXHIBIT 99.1
EXHIBIT 99.1
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications